Extina “Not Approvable” Decision Reflects Non-Superiority Over Placebo
This article was originally published in The Pink Sheet Daily
Executive Summary
Connetics’ ketoconazole foam for seborrheic dermatitis was not superior to placebo foam in a pivotal study, although it met the primary endpoint of non-inferiority to an active comparator. The company will decide whether to pursue approval in relation to other pipeline projects.
You may also be interested in...
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).
No More NASHing Of Teeth: Madrigal’s Resmetirom Approval Ends Years Of Industry Frustration
US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.
Publisher’s Spotlight: The Citeline Awards Are Open For Entries!
Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees.